(PCRX) Pacira BioSciences, Inc. Marketing Mix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(PCRX) Pacira BioSciences, Inc. Complete Analysis Pack
See the Bigger Picture
This Pacira BioSciences, Inc. 4P's Marketing Mix Analysis explains the company’s product lineup (e.g., non-opioid pain therapies), how those products are used, and how pricing, distribution, and promotion support adoption — the page shows a real preview/sample of the report so you can evaluate style and content before buying; purchase the full version to get the complete ready-to-use analysis.
Product
EXPAREL injectable liposomal bupivacaine
EXPAREL injectable liposomal bupivacaine is Pacira BioSciences, Inc.’s flagship branded product for postsurgical pain control. It is an injectable, extended-duration local anesthetic used by healthcare professionals in perioperative care. The 266 mg dose supports a non-opioid pain option.
In the Product mix, EXPAREL anchors Pacira’s premium, physician-driven portfolio with hospital and surgical use cases. Its liposomal delivery helps extend local analgesia beyond standard bupivacaine.
That position matters in a market still pressured by opioid-sparing care, where faster recovery and lower opioid use are key buying points.
ZILRETTA extended-release triamcinolone acetonide
ZILRETTA is Pacira BioSciences, Inc.’s 32 mg extended-release triamcinolone acetonide injection for knee osteoarthritis pain, designed to release steroid over about 12 weeks versus standard injections that fade faster. It strengthens Pacira’s non-opioid pain mix beyond surgery, adding a chronic-care product with broad physician use in the U.S. Medicare-linked OA market of millions.
iovera handheld cryoanalgesia system
iovera is Pacira BioSciences, Inc.’s non-opioid, handheld cryoanalgesia system that uses controlled cold to interrupt pain signals for procedure-based care. It helps clinicians manage pain without drugs, which fits a cleaner, lower-opioid treatment mix. In Pacira BioSciences, Inc.’s 2025 product set, it supports growth in non-opioid pain care across outpatient and surgical settings.
MVL drug delivery technology
Pacira BioSciences, Inc.’s MVL platform uses multivesicular liposomes to hold therapeutic compounds and release them over time, helping keep the drug’s structure intact. It is the core science behind Exparel, which generated $679.7 million in net sales in 2025 and shows how formulation can drive long-duration pain control.
That delivery tech gives Pacira a clear product edge: longer release, fewer doses, and a stronger base for pipeline work.
- Multivesicular liposomes extend release.
- Protects molecule structure.
- Supports Exparel and future products.
Non-opioid pain and regenerative health focus
Pacira BioSciences, Inc. centers its pain portfolio on non-opioid care, led by EXPAREL for postsurgical pain and iovera° for cryoanalgesia. This fits hospitals, ambulatory surgery centers, orthopedics, and other physician-administered sites, where 1 patient move away from opioids can matter. The model clearly separates Company Name from opioid-based pain drugs.
- Non-opioid pain focus
- Hospital and ASC channels
- Orthopedic physician use
- Opioid-sparing differentiation
EXPAREL Drives Pacira’s Non-Opioid Pain Care Growth
Pacira BioSciences, Inc. centers Product on non-opioid pain care, led by EXPAREL, a 266 mg liposomal bupivacaine injection for postsurgical pain. In 2025, EXPAREL delivered $679.7 million in net sales, making it the core product and the main proof point for Pacira’s liposomal delivery platform.
| Product | Use | 2025 Sales |
|---|---|---|
| EXPAREL | Postsurgical pain | $679.7M |
| ZILRETTA | Knee OA pain | N/A |
| iovera° | Cryoanalgesia | N/A |
What is included in the product
Detailed Word Document
A concise, company-specific 4P’s analysis of Pacira BioSciences, Inc.’s product, pricing, distribution, and promotion strategy.
Editable Excel File
Summarizes Pacira BioSciences’ 4Ps as a quick pain-point reliever for fast, clear marketing insight.
Reference Sources
Provides a concise, traceable bibliography of industry reports, peer-reviewed studies, SEC filings, and pricing benchmarks to speed due diligence on Pacira BioSciences.
Place
United States market
Pacira BioSciences, Inc. sells its products in the United States, where the healthcare system served 334 million people in 2025. Its commercial model is built on domestic hospital, surgical, and ambulatory provider access, so U.S. clinical adoption drives demand. The United States also remains the world’s largest healthcare market, with spending above $4.9 trillion.
Tampa, Florida headquarters
Pacira BioSciences, Inc.’s main corporate office is in Tampa, Florida, where finance, legal, HR, and strategy are run. The site anchors its U.S.-based operations and supports the company’s commercial footprint across the country.
Hospital and surgical center channels
Pacira BioSciences, Inc. sells mainly through hospitals and outpatient surgery centers, where physician-administered pain products are used at the point of care. These sites matter most because they handle surgeries and immediate post-op pain treatment, so access to the right formulary and buying committee drives sales. This channel keeps Pacira close to clinicians and high-volume procedures, not retail buyers.
Provider-driven access model
Pacira BioSciences, Inc. sells through a provider-driven channel: clinicians choose the product, hospitals add it to formularies, and purchasing teams set access rules. That makes it a B2B healthcare model, not consumer retail, so adoption depends on protocol wins and institutional contracts more than shelf visibility.
- Clinician-led product selection
- Formulary and protocol gate access
- Hospital purchasing drives volume
- B2B, not direct-to-consumer
Specialty healthcare sales network
Pacira BioSciences uses a specialty healthcare sales network to reach prescribers and procedure sites with high-touch clinical education and account support. This model fits its surgical and procedure-based products, where adoption depends on in-service training, reimbursement help, and facility-level follow-up. The channel is built for narrow, specialist demand rather than broad retail reach.
In 2025, that focused field force supported a business with about $600 million in annual net sales, so each account matters. The network helps convert clinical evidence into routine use in hospitals and ambulatory surgery centers.
Pacira’s U.S. hospital-first channel drives institutional access
Pacira BioSciences, Inc. keeps "Place" tightly focused on the U.S., selling through hospitals and ambulatory surgery centers where clinician-led, point-of-care use drives adoption. Its Tampa, Florida headquarters supports national sales, access, and operations. This B2B setup makes formulary wins and institutional access the key to reach.
| Place factor | Detail |
|---|---|
| Market | United States |
| Channel | Hospitals and ASCs |
| HQ | Tampa, Florida |
Get Your Copy
Pacira BioSciences, Inc. Reference Sources
The preview shown here is the actual Pacira BioSciences 4P's Marketing Mix analysis you’ll receive instantly after purchase—no surprises; it’s a complete, editable document covering Product, Price, Place, and Promotion tailored to Pacira’s market position and strategy.
Promotion
Healthcare professional education
Pacira BioSciences, Inc. promotes its products mainly to clinicians, with education centered on clinical evidence, dosing, and where each therapy fits in pain pathways. This is meant to win adoption with surgeons, anesthesiologists, and orthopedists, who drive perioperative pain decisions. The focus is practical: better evidence, clearer use, and faster uptake in operating rooms.
Non-opioid awareness messaging
Pacira BioSciences, Inc. uses non-opioid awareness messaging to push opioid-sparing pain care, led by EXPAREL, which has been used in over 10 million patients. The message spotlights the clinical value of non-opioid options and ties the brand to safer recovery paths. It fits a market where opioid risk remains a major concern, with U.S. overdose deaths still above 100,000 a year.
Medical congress presence
Pacira BioSciences uses medical congresses to present clinical data and product outcomes to healthcare professionals, which helps turn study results into peer-level trust. In 2024, Company Name reported about $669 million in net product sales, so these meetings support a large, science-led brand.
Congress talks and posters give surgeons and anesthesiology teams a direct look at efficacy and safety data, which matters in pain care where evidence drives adoption. That face-to-face scientific presence also strengthens credibility with key opinion leaders and can support future prescribing decisions.
Field sales and account support
Pacira BioSciences’ field sales and account support teams work directly with health systems and clinics to teach product use, clear access hurdles, and help with rollout, which speeds adoption into routine care. This matters because Pacira reported about $620 million in 2024 net sales, so even small gains in conversion and repeat use can move revenue. The team’s hands-on model supports buying decisions, formulary access, and day-to-day implementation.
- Direct clinic education drives adoption.
- Access support reduces launch friction.
- Implementation help turns trials into routine use.
Payer and reimbursement support
Pacira BioSciences, Inc. uses payer and reimbursement support to lower access friction for physician-administered products like EXPAREL, where site-of-care coverage can decide uptake. Clear coding, prior-auth help, and institution-facing reimbursement guidance can speed adoption and reduce claim denials. That matters because specialty injectables often face more complex billing than retail drugs.
- Supports provider and hospital access
- Reduces reimbursement-related adoption barriers
Pacira’s EXPAREL Push: 10M+ Patients, $669M Sales
Pacira BioSciences, Inc. promotes EXPAREL with clinician education, congress data, and field support, aiming to win surgeons and anesthesiologists on evidence and workflow fit. It pairs opioid-sparing messaging with access and reimbursement help, and said EXPAREL has been used in over 10 million patients while 2024 net product sales were about $669 million.
| Metric | Data |
|---|---|
| EXPAREL use | 10M+ patients |
| 2024 net product sales | $669M |
Price
Branded premium pricing
Pacira BioSciences, Inc. uses branded premium pricing because its products are specialty therapeutics, not low-cost generics. EXPAREL is positioned for up to 72 hours of postsurgical pain control, so pricing is tied to clinical value and longer duration of effect, not unit cost. That brand-led model supports premium pricing in hospital care and helps defend margins.
Contract-based hospital pricing
Pacira BioSciences, Inc. uses contract-based hospital pricing, so access is often set with health systems, hospitals, and ambulatory surgery centers. Price can move by contract, volume, and buying terms, which is normal for institution-sold injectable medicines and devices. This model helps Pacira fit large accounts, where a single facility contract can cover thousands of patient doses and procedures.
Reimbursement-dependent economics
Pacira BioSciences, Inc. pricing is tied to payer coverage and reimbursement status, so hospitals and clinicians often buy only when the payment path is clear. That makes adoption of EXPAREL and ZILRETTA depend as much on coding and coverage as on clinical need. When reimbursement is slow or limited, real-world affordability drops and uptake can stall.
Value-based pain management positioning
Pacira BioSciences, Inc. prices on clinical and economic value, not just unit cost, because hospitals pay for fewer opioids, fewer complications, and faster recovery. That value-based pitch helps support adoption in cost-conscious settings, where avoiding even small extra care costs can matter more than a higher upfront price.
- Focuses on opioid-sparing outcomes
- Sells savings, not just price
- Fits hospital cost controls
Specialty physician-administered pricing model
Pacira BioSciences’ pricing is set in healthcare channels, not on a retail shelf, so hospitals, ASCs, and physicians buy through negotiated contracts and reimbursement rules. That makes price a "buy-and-bill" variable tied to provider administration, payer coverage, and site-of-care economics. For physician-administered drugs, Medicare Part B patients often face 20% coinsurance, so net realized price depends on reimbursement, not list price.
- Sold through provider channels
- Price set by contracts
- Tied to administration and reimbursement
- Net price varies by site of care
Pacira’s Premium Pricing Reflects EXPAREL’s 72-Hour Value
Pacira BioSciences, Inc. prices EXPAREL and ZILRETTA as premium, hospital-based therapies, so price tracks clinical value, not drug cost. Pricing is set through negotiated contracts and reimbursement rules, and that makes net realized price vary by site of care. For EXPAREL, the 72-hour pain-control profile supports a value-based price.
| Price driver | Key data |
|---|---|
| EXPAREL duration | Up to 72 hours |
| Patient coinsurance | 20% Medicare Part B |
| Pricing model | Negotiated contracts |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.